Marc Odrich, M.D., serves as the Chief Medical Officer at LENZ THERAPEUTICS INC, where he plays a pivotal role in guiding the company's clinical development and medical strategy. Dr. Odrich is a highly respected ophthalmologist with a robust background in both clinical practice and pharmaceutical development. He earned his medical degree from the New York University School of Medicine and completed his residency in ophthalmology at the prestigious Wills Eye Hospital in Philadelphia. His expertise spans various aspects of eye care, with a particular focus on refractive surgery and the treatment of presbyopia. Throughout his career, Dr. Odrich has made significant contributions to the field of ophthalmology. He has been involved in numerous clinical trials and has published extensively on topics related to ocular health and disease management. His work has been recognized in leading medical journals, and he is often invited to speak at international conferences. Prior to joining LENZ THERAPEUTICS INC, Dr. Odrich held key positions at several renowned institutions and pharmaceutical companies, where he helped develop innovative treatments for various eye conditions. As Chief Medical Officer at LENZ THERAPEUTICS INC, Dr. Odrich is instrumental in advancing the company's mission to develop novel therapies for presbyopia and other vision disorders. His leadership and deep understanding of the clinical landscape are crucial in steering the company's research and development efforts. Under his guidance, LENZ THERAPEUTICS INC aims to bring cutting-edge solutions to patients, improving their quality of life and addressing unmet medical needs in the field of ophthalmology.